Post-treatment neutrophil-lymphocyte ratio independently predicts amputation in XXXX without operation.

@entity1 @entity63
OBJECTIVES: Limited information is available concerning the post-treatment neutrophil-lymphocyte ratio in @entity63 @entity1 who receive conservative therapy. Accordingly, this study was designed to evaluate the predictive value of the post-treatment neutrophil-lymphocyte ratio in @entity63 @entity1 without surgery. METHOD: From January 2009 to January 2011, @entity63 @entity1 were admitted to a vascular center. The demographic data, @entity1 histories, comorbidities and risk factors were documented, and the differential cell count was determined at admission and seven days later after conservative therapy. The cutoff value of the post-treatment neutrophil-lymphocyte ratio was determined by an ROC curve. @entity1 were divided into groups A and B according to the cutoff value. Amputation-free survival was compared between groups. Univariate and multivariate analyses were used to identify independent risk factors. RESULT: A total of 172 @entity1 were identified with a mean age 71.98  10.09 years; among them, 122 were male. A value of 3.8 was identified as the cutoff value of the post-treatment neutrophil-lymphocyte ratio. Groups A (post-treatment neutrophil-lymphocyte ratio >= 3.8) and B (post-treatment neutrophil-lymphocyte ratio <3.8) showed a significant difference in amputation-free survival (P<0.001). The 1-year, 2-year and 3-year amputation-free survival rates were 79.6%, 55.6% and 46.3%, respectively, in group A; however, in group B, these values were 89.7%, 79.3% and 75.9%, respectively. The post-treatment neutrophil-lymphocyte ratio was identified as an independent predictive factor for amputation in @entity63 @entity1 (P<0.001). CONCLUSION: The post-treatment neutrophil-lymphocyte ratio is an independent predictive factor for amputation in @entity63 @entity1 . @entity1 with a post-treatment neutrophil-lymphocyte ratio >= 3.8 are likely to suffer from amputation; amputation-free survival usually occurs in @entity1 with a post-treatment neutrophil-lymphocyte ratio <3.8.
